CHAPEL HILL, N.C.--(BUSINESS WIRE)-- iOrganBio has officially emerged from stealth mode with $2 million in initial funding, marking a significant step forward in the future of human cell manufacturing. The round was led by First Star Ventures, with additional support from institutional investors including IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, and Alix Ventures. At the core of iOrganBio’s mission is the launch of CellForge™, the company’s proprietary AI-powered platform designed to revolutionize the way human cells and organoids are engineered and produced. By integrating advanced artificial intelligence for predictive modeling with high-throughput experimental automation, CellForge™ enables rapid, precise, and scalable cell manufacturing across a range of high-impact applications. The platform is built to address long-standing challenges in cell production, such as variability, low yield, and lengthy development timelines. With AI-driven insights, researchers can now design and optimize cell manufacturing processes in a fraction of the time, significantly accelerating drug discovery, regenerative medicine, and disease modeling. iOrganBio’s technology is particularly well-suited for applications in oncology, neurodegenerative diseases, and personalized medicine, where consistent, high-quality human cell models are essential. By reducing reliance on traditional, labor-intensive methods, CellForge™ aims to democratize access to reliable cellular systems for biotech and pharmaceutical companies. The company’s founding team brings deep expertise in AI, synthetic biology, and biomedical engineering, positioning iOrganBio at the intersection of cutting-edge technology and life sciences innovation. With this initial funding, the company plans to expand its platform capabilities, strengthen its team, and begin pilot collaborations with leading research institutions and biopharma partners. As the field of regenerative medicine and cell-based therapies continues to grow, iOrganBio’s AI-driven approach represents a new paradigm in how biological systems are designed and manufactured—faster, smarter, and more scalable than ever before.